Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 5/20 | 0.39 |
| ▸ | CASP3 | P42574 | 7/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FER | P16591 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10914947 | 0.88 | GSK3B (0.45) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL11015946 | 0.88 | GSK3B (0.45) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL11206986 | 0.88 | GSK3B (0.45) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL10712855 | 0.88 | GSK3B (0.45) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL5970012 | 0.86 | GSK3B (0.50) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL6598413 | 0.83 | KDM4E (0.43) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL5312970 | 0.83 | GSK3B (0.41) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL34459996 | 0.83 | CDK2 (0.42) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL166776 | 0.83 | ELANE (0.43) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL335247 | 0.83 | GSK3B (0.41) | GSK3BKDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809368-B2 | Compounds affecting gap junction activity | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-7566549-B2 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090143425-A1 | COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2007127930-A2 | COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-11-08 | — | — | WO | disclosed |
| US-7271252-B2 | Reagents for detecting efavirenz | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070122859-A1 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | GHOSHAL MITALI | 2007-05-31 | — | — | US | disclosed |
| US-7157560-B2 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060088933-A1 | Reagents for detecting efavirenz | SIGLER GERALD F | 2006-04-27 | — | — | US | disclosed |
| US-20040214251-A1 | Reagents for detecting efavirenz | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2004-10-28 | — | — | US | disclosed |
| EP-1470825-A1 | Reagents for detecting efavirenz | Roche Diagnostics GmbH (DE) | 2004-10-27 | — | — | EP | disclosed |
| US-6794496-B2 | 2-OXO-DERIVATIVES OF LSD; HAPTEN DERIVATIVES USED TO PREPARE ANTIGENS, ANTIBODIES AND REAGENTS FOR USE IN IMMUNOASSAYS. | ROCHE DIAGNOSTICS CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20030013131-A1 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20010044118-A1 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2001-11-22 | — | — | US | disclosed |
| EP-1148339-A2 | Immunoassay for LSD and 2-Oxo-3-Hydroxy-LSD | Roche Diagnostics Corporation (US) | 2001-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044118-A1 | Immunoassay for LSD and 2-oxo-3-hydroxy-LSD | HNMT, HRH3, HRH4 | GSK3B 3797/4885KDM4E 447/4885ALDH1A1 2475/4885 |
| US-20090143425-A1 | COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY | GJB2, GJA1, GAP43 | GSK3B 1455/4885KDM4E 2984/4885ALDH1A1 3639/4885 |
| US-20040214251-A1 | Reagents for detecting efavirenz | SAMHD1, CYP2F1, CD4 | GSK3B 1531/4885KDM4E 1364/4885ALDH1A1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.